New Trials Offer Hope for Type 1 Diabetic Kidney Disease

by admin | May 7, 2026 | Health

Spread the love

At the FSED meeting, investigators highlight SGLT2 inhibitors, finerenone, and GLP-1 or GIP agents as promising strategies to slow kidney decline and cut CV risk in type 1 diabetes.
Medscape News Europe

← Bariatric Surgery Linked to Higher Nutrient Deficiency Risk Seven Britons Left Hantavirus Ship Mid-Voyage →

Written By

Written by Albert Pham, News Curator and Blogger

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

New Trials Offer Hope for Type 1 Diabetic Kidney Disease

Written By

Related Posts

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated